AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese zucker rats

Journal of Lipid Research

Volumn 43, Issue 11, 2002, Pages 1855-1863

  Ljung, Bengt ^a   Bamberg, Krister ^a   Dahllöf, Björn ^a   Kjellstedt, Ann ^a   Oakes, Nicholas D ^a   Östling, Jörgen ^a   Svensson, Lennart ^a   Camejo, Germán ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Hypertriglyceridemia; Peroxisome proliferator activated receptor; Type 2 diabetes

Indexed keywords

CYTOCHROME P450 4A; FATTY ACID BINDING PROTEIN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TESAGLITAZAR; UNCLASSIFIED DRUG; (S) 2 ETHOXY 3 (4 (2 (4 METHYLSULPHONYLOXYPHENYL)ETHOXY)PHENYL)PROPANOIC ACID; (S)-2-ETHOXY-3-(4-(2-(4-METHYLSULPHONYLOXYPHENYL)ETHOXY)PHENYL)PROPANOIC ACID; BEZAFIBRATE; CELL RECEPTOR; CINNAMIC ACID DERIVATIVE; FATTY ACID; GLUCOSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INDUCTION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; DIABETES MELLITUS; DRUG POTENTIATION; MASS SPECTROMETRY; METABOLISM; MOUSE MUTANT; OBESITY; PHYSIOLOGY; ZUCKER RAT;

ANIMALS; BEZAFIBRATE; CARBOHYDRATE METABOLISM; CINNAMATES; DIABETES MELLITUS; FATTY ACIDS; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MASS SPECTROMETRY; MICE; MICE, OBESE; MOLECULAR STRUCTURE; OBESITY; RATS; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0036847135     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200127-JLR200     Document Type: Article

References (42)

1. Grundy, S., I. Benjamin, G. Burke, A. Chait, R. Eckel, B. Howard, W. Mitch, S. Smith, and J. Sowers. 1999. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 100: 1134-1146.
2. Isomaa, B., P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M. R. Taskinen, and L. Groop. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24: 683-689.
3. Zimmet, P., K. Alberti, and J. Shaw. 2001. Global and societal implications of the diabetes epidemic. Nature. 414: 782-787.
4. Randle, P. J. 1998. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14: 263-283.
5. Packard, C. J. 1999. Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. Curr. Opin. Lipidol. 10: 237-244.
6. Sniderman, A. D., T. Scantlebury, and K. Cianflone. 2001. Hypertriglyceridemic hyperapob: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann. Intern. Med. 135: 447-459.
7. Moller, D. E. 2001. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 414: 821-827.
8. Fajas, L., M. B. Debril, and J. Auwerx. 2001. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis. J. Mol. Endocrinol. 27: 1-9.
9. Torra, I. P., G. Chinetti, C. Duval, J. C. Fruchart, and B. Staels. 2001. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice. Curr. Opin. Lipidol. 12: 245-254.
10. Auwerx, J. 1999. PPARγ, the ultimate thrifty gene. Diabetologia. 42: 1033-1049.
11. Willson, T. M., M. H. Lambert, and S. A. Kliewer. 2001. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu. Rev. Biochem. 70: 341-367.
12. Oakes, N., P. Thalén, S. Jacinto, and B. Ljung. 2001. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes. 50: 1158-1165.
13. Kersten, S., J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103: 1489-1498.
14. Ye, J. M., P. J. Doyle, M. A. Iglesias, D. G. Watson, G. J. Cooney, and E. W. Kraegen. 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes. 50: 411-417.
15. Lebovitz, H. E., J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed. 2001. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86: 280-288.
16. Miyazaki, Y., A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L. J. Mandarino, and R. A. DeFronzo. 2001. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 24: 710-719.
17. Fruchart, J-C., P. Duriez, and B. Staels. 1999. Peroxisosme proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245-257.
18. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, T. J. Wilt, and J. Wittes. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341: 410-418.
19. Linton, M. F., and S. Fazio. 2000. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Curr. Atheroscler. Rep. 2: 29-35.
20. Steiner, G. 2001. Effect of fenofibrate on progression of coronaryartery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet. 357: 905-910.
21. Guerre-Millo, M., P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J-M. Herbert, D. A. Winegar, T. M. Willson, J-C. Fruchart, R. K. Berge, and B. Staels. 2000. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275: 16638-16642.
22. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdoff, and J. C. Fruchart. 1998. Mechanism of actions of fibrates on lipid and lipoprotein metabolism. Circulations. 98: 2088-2093.
23. Shibata, T., K. Matsui, F. Yonemori, and K. Wakitani. 1999. Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501. Eur. J. Pharmacol. 373: 85-91.
24. Willson, T., P. Brown, D. Sternbach, and B. Henke. 2000. The PPARs: From orphan receptors to drug discover. J. Med. Chem. 43: 527-550.
25. Pineda, I., G. Chinetti, C. Duval, J-C. Fruchart, and B. Staels. 2001. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice. Curr. Opin. Lipidol. 12: 245-254.
26. Schoonjans, K., G. Martin, B. Staels, and J. Auwerx. 1997. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8: 159-166.
27. Chinetti, G., S. Lestavel, V. Bocher, A. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H. B. Brewer, J. C. Fruchart, V. Clavey, and B. Staels. 2001. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58.
28. Cronet, P., J. F. W. Petersen, R. Folmer, N. Blomberg, K. Sjoblom, U. Karlsson, E. L. Lindstedt, and K. Bamberg. 2001. Structure of the PPAR[alpha] and -[gamma] ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure. 9: 699-706.
29. Murakami, K., K. Tobe, T. Mochizuki, M. Ohashi, Y. Akanuma, Y. Yazaki, and T. Kadowaki. 1998. A novel insulin sensitizer acts as a ligand for peroxisome proliferator-activated receptor-alpha and PPAR-gamma. Diabetes. 47: 1841-1847.
30. Etgen, G. J., B. A. Oldham, W. T. Johnson, C. L. Broderick, C. R. Montrose, J. T. Brozinick, E. A. Misener, J. S. Bean, W. R. Bensch, D. A. Brooks, A. J. Shuker, C. J. Rito, J. R. McCarthy, R. J. Ardecky, J. S. Tyhonas, S. L. Dana, J. M. Bilakovics, J. R. Paterniti, K. M. Ogilvie, S. Liu, and R. F. Kauffman. 2002. A tailored therapy for the metabolic syndrome - The dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes. 51: 1083-1087.
31. Sauerberg, P., I. Pettersson, L. Jeppesen, P. S. Bury, J. P. Mogensen, K. Wassermann, C. L. Brand, J. Sturis, H. F. Woldike, J. Fleckner, A. S. T. Andersen, S. B. Mortensen, L. A. Svensson, H. B. Rasmussen, S. V. Lehmann, Z. Polivka, K. Sindelar, V. Panajotova, L. Ynddal, and E. M. Wulff. 2002. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPAR alpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45: 789-804.
32. Edvardsson, U., M. Bergström, M. Alexandersson, K. Bamberg, B. Ljung, and B. Dahllöf. 1999. Rosiglitazone (BR49653), a PPAR-gamma selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J. Lipid Res. 40: 1177-1184.
33. Romano, M., K. Straub, L. Yodis, R. Eckhardt, and J. Newton. 1988. Determination of microsomal lauric hydroxylase activity by HPLC with flow-through rediochemical quantification. Anal. Biochem. 170: 83-93.
34. Garcia de Herreros, A., and M. J. Birnbaum. 1989. The acquisition of increased insulin-responsive hexose transport in 3T3-L1 adipocytes correlates with expression of a novel transporter gene. J. Biol. Chem. 264: 19994-19999.
35. Lanne, B., F. Potthast, A. Hoglund, H. Brockenhuss von Löwenhielm, A. C. Nystrom, F. Nilsson, and B. Dahllöf. 2001. Thiourea enhances mapping of the proteome from murine white adipose tissue. Proteomics. 1: 819-828.
36. Tontonoz, P., E. Hu, and B. Spiegelman. 1995. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Develop. 5: 571-576.
37. Sturis, J., W. Pugh, J. Tang, and K. Polonowski. 1995. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am. J. Physiol. 269: E786-E792.
38. Smith, S., C. Lister, C. Toseland, and R. Bukingham. 2000. Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker diabetic fatty rat. Diabetes. Obes. Metab. 2: 363-372.
39. Unger, R., and L. Orci. 2001. Diseases of liporegulation: New perspectives on obesity and related disorders. FASEB J. 15: 312-321.
40. Oakes, N., C. Kennedy, A. Jenkins, D. Laybutt, D. Chisholm, and E. Kraegen. 1994. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes. 43: 1203-1210.
41. Kroetz, D., P. Yook, P. Costet, P. Bianchi, and T. Pineau. 1998. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptative response to starvation and diabetes. J. Biol. Chem. 47: 31581-31589.
42. Simpson, A. E. 1997. The cytochrome P450 4 (CYP4) family. Gen. Pharmacol. 28: 351-359.